Seroma Volume Changes

Presented by Wesley Zoller, B.S.R.T.(T) Medical Dosimetry Student June 19th, 2013 AAMD Annual Meeting San Antonio, TX

A Little Background on Me

I’m a Country Fella from Churchtown, Ohio

• Small little farming community by the Ohio River

My Family!

B.S.RT(T) from the Ohio State University (2012)

Cleveland Browns Fan…..

Honorary Spurs Fan for these few weeks…

Student in the Cleveland Clinic CMD Program

• Graduating July 19th, 2013!!!!

When I have time, I like to do a little golfing…

Presented by Wesley Zoller, B.S.R.T.(T) Medical Dosimetry Student June 19th, 2013 AAMD Annual Meeting San Antonio, TX

Aims of the Study

Objectives

• Quantify the changes in seroma volume over the course of RT for early stage breast cancer patients eligible for RTOG 1005.

• Evaluate the dosimetric impact of these changes on sequential boost planning in accordance with Arm I of RTOG 1005.

• Assess the need for adaptive planning and pre-boost CT acquisition for sequentially boosted breast cancer patients based on evaluation with RTOG 1005 criteria.

• Dosimetrically compare two hypofractioned boost methods, concurrent electron versus concomitant tangential IMRT photon, with the planning/evaluation criteria outlined in Arm II of RTOG 1005.

Background of RTOG 1005

Reference 1 on Final Slide


• For Early Stage Breast Cancer Patients (Stage I-II)

• Post-Lumpectomy Breast Conservation Course

• Shorten Treatment Time

• Objectives of Study

• Primary: determine if accelerated hypofractionated WBI with concomitant tumor bed boosting is non-inferior in local control to Standard of Care sequential boost and fractionation scheme

• Secondary: determine if ARM II is non-inferior to the Standard of Care in terms of cosmesis, treatment symptoms (3 weeks and at 3 years), cardiac toxicity for left sided cases, and treatment costs

• If non-inferior, determine if ARM II hypofractionated scheme is superior to Standard of Care fractionated in same criteria

Previous Literature

• 2009 study, aimed to evaluate the change in seroma volume over WBRT prior to boost planning.

• 24 patients with evident seroma on initial CT, received 42.4Gy/16fx with 9.6Gy/4fx boost or 50.4Gy/28fx WBRT with 10Gy/5fx boost

• Second CT acquired at 3-5 weeks, dependent upon fractionation schedule

• Mean CT1 seroma was 65.7 cc and CT2 was 35.6 cc. Mean reduction of 39.6% with an SD of 23.8%, p<0.001, 2 of 24 patients showed increase in size with an increase or 9.7% and 10.7%

• Changes during WBRT found to be significant and group concluded boost planning accuracy can be affected by these changes.



• 2009 study, aimed to determine if lumpectomy cavity decreases in volume during whole breast radiotherapy and contributing factors.

• 43 patients, 44 breast lesions prospectively enrolled. Lumpectomy and CT sim within 60 days of surgery. WBRT 45-50.4 Gy.

• CT2 acquired b/w 21-23 treatments, seroma contoured on new CT and compared.

• Mean volume was 38.2 cc on CT1, 21.7 cc on CT2. Mean decrease of 32% and 11.2 delta cc. Decreased on 38 of 44 patients (86%), p<0.001

• Concluded that tracking change and acquiring a pre-boost CT can lead to decreased doses of radiation to remaining breast and critical structures, and should be considered in patients with larger cavities.

Methods

Summary of Methods

• 11 early stage breast cancer patients eligible for RTOG 1005

• Clinically evident seroma at time of initial simulation (CT1)

• Received second CT (CT2) prior to planning of sequential boost

• Seroma volume/Lumpectomy GTV delineated on both datasets

• PHASE I: Characteristics of both CT1 and CT2 seroma volumes recorded

• Fusion of CT2 dataset and contour onto CT1 dataset

• In accordance with RTOG 1005 Arm I, patients retrospectively re-planned giving 50Gy/25fx to whole breast and boosting sequentially with 12Gy/6fx given via electron boost to the cavity (Standard of Care Arm)

• Boost plans individually optimized for each volume (CT1 vs. CT2)

• Plans compared based on dose to Heart, Ipsilateral Lung, Breast PTV Eval (Normal Breast), and coverage of Lumpectomy PTV Eval using specified Arm I evaluation criteria

Summary of Methods

• PHASE II: Comparison of Concurrent Hypofractionated Boost Methods

• In accordance with RTOG 1005 Arm II, patients retrospectively re-planned giving 40Gy/15fx to whole breast tangents and boosting concurrently with 8 Gy in the same 15 fx

• Boost plans individually optimized for CT1 target volumes

• Concurrent Electron Cavity Boost

• Concomitant IMRT Photon Cavity Boost

• Plans compared based on dose to Heart, Ipsilateral Lung, Breast PTV Eval (Normal Breast), and coverage of Lumpectomy PTV Eval using specified Arm II evaluation criteria

Contouring for the Study (Using RTOG 1005 Delineation Guidelines)

Lumpectomy GTV (per RTOG 1005) • Excision cavity volume, architectural distortion, lumpectomy scar,

seroma and/or extend of surgical clips (clips strongly recommended)

Lumpectomy CTV (per RTOG 1005) • Lumpectomy GTV + 1 cm 3D Expansion, Limiting Borders: Pectoralis

and Serratus Anterior Muscles, Midline, and 5 mm from skin surface

Lumpectomy PTV (per RTOG 1005) • Lumpectomy CTV + 7 mm uniform 3D Expansion (Excluding Heart)

Lumpectomy PTV Eval (per RTOG 1005) • Lumpectomy PTV minus area outside of ipsilateral breast, first 5 mm

of skin, and the chest wall/pectoralis muscles/lungs.

Breast PTV Eval (per RTOG 1005) • Breast CTV (palpable breast volume – CW and 5mm skin) + 7 mm PTV

expansions in same Manner as Lumpectomy PTV Eval (avoid CW, 5mm)

Critical Normal Structures (per RTOG 1005) • In this study: Ipsilateral Lung, Heart (Split of Pulmonary trunk into

Pulmonary Arteries superiorly to apex inferiorly), and Contralateral Lung.

Image Fusion

GTV Delineation (RTOG 1005) and Image Fusion

CT1 GTV Delineation CT2 GTV Delineation

GTV Delineation (RTOG 1005) and Image Fusion

Box-Based Fusion using chest wall and Ipsilateral Breast

CT-CT Fusion done in PhilipsTM Pinnacle® SyntegraTM

Evaluation/Results of Seroma Volume Changes CT1 versus CT2 Volume

Results – Table 1 Seroma Volume Changes

Max Percent Decrease = 77.3%

Min Decrease = 46.1%

Planning for Phase I: Sequential Electron Boost for CT1 and CT2 (RTOG Arm I)

Phase I of Study, Sequential Boosting (Arm I)

• 11 patients, retrospectively re-planned for 50 Gy in 25 fractions tangentially to the whole breast.

• Sequential Electron boosts given 12 Gy in 6 fractions to Lumpectomy GTV using Lumpectomy PTV as Block Margin

• Optimized for both CT1 and CT2 Scans for the 11 patients (Available MEV 6, 9, 12, 15, 18, 21)

Phase I of Study, Sequential Boosting (Arm I)

Boost BEV for CT1 Volume Boost BEV for new CT2 Volume

Evaluation of Sequential Boost (RTOG Arm I) Phase I: CT1 versus CT2 Seroma Volume

V58.9 of Lumpectomy PTV Eval >/= 95% (Arm I)

V47.5 of Breast PTV Eval >/= 95% (Arm I)

V56 of Breast PTV Eval </= 50% (Arm I)

V62 of Breast PTV Eval </= 30% (Arm I)

V20 of Ipsilateral Lung </= 20% (Arm I)

Mean Heart Dose < 500 cGy (RTOG 1005 Arm I)

Results for Sequential Boost (RTOG Arm I) Phase I: CT1 versus CT2 Seroma Volume

Comparison (Phase I)

For Phase I, the lung and heart dose are comparable for both plans.

However, V56 of Breast PTV Eval drops by 6.8% for boost plan optimized to new volume

Phase I of Study, Sequential Boosting (Arm I) • Comparison of Sequential Electron Boosts

Boost Plan for Lumpectomy PTV Eval CT1 Boost Plan for Lumpectomy PTV Eval CT2

Reduced V56 for Re-CT Optimized Plan

59.8 Gy

56 Gy

47.5 Gy

20 Gy

Results - Table 2 for Sequential Boost (Phase I)

Comparison of V58.9 of Lumpectomy PTV Eval

Old Plan still maintains coverage of re-scan Lumpectomy PTV Eval

Planning for Phase II: Hypofractionated Concurrent Electron versus Concomitant IMRT Photon (RTOG Arm II)

Phase II of Study, Hypofractionated Course with Concurrent Boosting (Arm II) • 11 patients, retrospectively re-planned for 40 Gy in 15 fractions

tangentially to the whole breast.

Phase II of Study, Hypofractionated Course with Concurrent Boosting (Arm II)

• Concurrent Electron Boost (Same blocking as Initial Sequential Phase I) given concurrently 8 Gy over 15 fractions for 11 patients

• 8 Gy Concomitant IMRT Photon Boost “mini-tangents” for same 11 patients

Evaluation of Concurrent Boost on Hypofractionated Course (RTOG Arm II) Phase II: Electron versus Concomitant IMRT Photon

V45.6 of Lumpectomy PTV Eval >/= 95% (Arm II)

V38 of Breast PTV Eval >/= 95% (Arm II)

V44.8 of Breast PTV Eval </= 50% (Arm II)

V48 of Breast PTV Eval </= 30% (Arm II)

V16 of Ipsilateral Lung </= 20% (Arm II)

Mean Heart Dose < 400 cGy (RTOG 1005 Arm II)

Results for Concurrent Boost on Hypofractionated Course (RTOG Arm II) Phase II: Electron versus Concomitant IMRT Photon

For Phase II, the ipsilateral lung and heart dose are comparable for both plans.

However, V44.8 of Breast PTV Eval dropped by 28.1% for Electron Boost vs. IMRT Photon Boosts

Comparison (Phase II)

45.6 Gy

44.8 Gy

38 Gy

16 Gy

Phase II of Study, Concurrent Hypofractionated Boosting (Arm II)

Much higher V44.8 for Concomitant IMRT Photon Boost Plan

Concurrent 8 Gy Electron Boost Concomitant 8 Gy Photon IMRT Boost

• Comparison of Boost Methods

Results - Table 3 for Hypofractionated Concurrent Boost (Phase II)

Discussion

Discussion

• Average seroma volume decrease of 57.1% +/- 8.96% from CT1 to CT2

• Time elapsed between CT acquisition was 33.6 days +/- 5.1 days

• ARM I SEQUENTIAL: V56 for Breast PTV Eval decreased by an average of 9.2% +/- 3.3% by optimizing the boost plan on a 2nd CT for the current standard of care WB + Boost (50 Gy + 12 Gy Boost)

• Lung and Heart Dose discrepancies were minimal b/w plans

• Coverage of Lumpectomy PTV Eval CT2 volume maintained using CT1-optimized plan

• Under-treating not found to be a concern in this study

• ARM II Hypofractionated: V44.8 for Breast PTV Eval decreased by an average of 16.2% +/- 8.1% on all Electron Boosts when compared to concomitant IMRT photon boost methods

• Lung and Heart Dose discrepancies were minimal b/w plans

Discussion

• Findings showed significant dose differences to the Breast PTV Eval

• Reduced by re-planning sequential boost using pre-boost CT

• Reduced using electron boost versus IMRT photon

• Significance of findings?

• Beyond WB prescription, breast tissue deemed to be normal tissue

• Reducing amount of normal breast tissue in boost field could potentially decrease some of the acute side effects associated with treatment of the site4,5

• Potential also exists to reduce late effects from breast irradiation, such as the development of fibrosis4,5

• RTOG 1005 does not currently allow planning from a pre-boost CT

• 2008 trial to investigate predictors of long-term risk of fibrosis

• Between 1989 and 1996, 5318 patients receive 50 Gy/25 fx WBRT

• 2661 not boosted, 2657 boosted w/ 16 Gy/8fx with electrons to tumor bed

• Median Follow-up 10.7 years in both, 1079 pt (20.8%) had developed moderate or severe fibrosis, 482 (9.3%) local recurrences, and 1013 (19.6% ) died

• Development dataset: 26.9% in boost arm had moderate or severe fibrosis versus 12.6% in non-boosted

• Boost reduced the risk of local recurrence by 41%


Conclusions

Take Home Message • Breast volume beyond tangential prescription should be treated as normal

tissue and should be spared as much as possible

• Potential to minimize both acute and late RT effects

• Adaptive Planning, or optimizing using a pre-boost CT showed to significantly decrease excess irradiation to normal breast tissue

• Electron cavity boosting also showed to be significantly superior to photon mini-tangents

• Lung and Heart dose discrepancies minimal between respective comparisons

• Simply acquiring one CT and adaptively optimizing a new boost plan has the potential to significantly decrease excess dose to normal breast tissue

• 4th or so week of treatment, ample time for dosimetry to generate boost plan

• In a world of CBCT and IGRT, the simple acquisition of one additional CT may be considered worthwhile in terms of potential to better patient outcomes

References and Co-authors of Manuscript

Thank you all so much for your time and your attention!!!

Have a great afternoon and everyone travel home safely!!!

Seroma Volume Changes

Documents

Transcript of Seroma Volume Changes